<DOC>
	<DOCNO>NCT00074412</DOCNO>
	<brief_summary>The many benefit breastfeed well document . However , risk mother-to-child transmission ( MTCT ) HIV HIV infect mother infant , considerable concern practice , especially develop country . The purpose study determine safety effectiveness anti-HIV drug nevirapine ( NVP ) prevent MTCT HIV breastfeed infant bear HIV infected woman South Africa , Tanzania , Uganda , Zimbabwe .</brief_summary>
	<brief_title>Using Nevirapine Prevent Mother-to-Child HIV Transmission During Breastfeeding</brief_title>
	<detailed_description>Breastfeeding provide general health , growth , development benefit infant significantly decrease risk certain acute chronic disease . Breastfeeding also decrease financial burden mother decrease need infant formula health care infant . However , clinical evidence show HIV readily transmit breast milk , although risk HIV MTCT time breastfeed difficult determine . Given many advantage breastfeed significant obstacle substitute formula breast milk develop country , urgent need make breastfeed HIV infected woman safe . This study evaluate safety efficacy extend NVP regimen prevention MTCT HIV breastfeeding . This study last approximately 3.5 year . Mother/infant pair enrol period 18 24 month . During third trim pregnancy , HIV infect participant receive HIV counsel intrapartum/neonatal two-dose NVP prophylaxis regimen prevent MTCT . Mothers also give infant feeding option counsel information administer study drug infant . Infants randomly assign receive placebo old 6 week age 08/10/07 OR receive NVP continue treatment assignment . Infants randomly assign receive placebo 6 week age le 08/10/07 receive open-label NVP Day 42 life . For participant , randomize infant receive extend NVP 6 week ( Day 42 ) life . All eligible infant randomly assign one two group Week 6 follow birth . The first group receive extend NVP treatment ; second group receive nevirapine placebo . Randomized infant receive extend NVP NVP placebo first 6 month life cessation breastfeeding , whichever occur early . Mothers instruct begin give infant assign intervention start Day 3 Day 7 postpartum . All mother infant outside study offer local standard care antiretroviral ( ARV ) regimen prevention MTCT , ARVs provide study . Follow-up evaluation conduct Weeks 2 6 Months 3 , 6 , 12 , 18 mother , Weeks 2 , 5 , 6 , 8 Months 3 , 4 , 5 , 6 , 9 , 12 , 18 infant . Study visit include physical examination , blood test ( include HIV test ) , medical history . Study participant follow 3.5 year .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<criteria>Note : As 08/10/07 , arm assignment current new participant change . Please see description trial information . Inclusion Criteria Mothers : 18 year age old HIV infect In third trimester pregnancy , 3 day postdelivery If baby yet bear , plan deliver facility study conduct Plan breastfeed Exclusion Criteria Mothers : Complications pregnancy Serious medical condition would interfere study ( e.g. , would prevent breastfeed adherence followup schedule ) , judge onsite clinician Inclusion Criteria Infants : Born HIV infect mother eligible study Weighed least 2000 gram ( 4.4 lb ) birth Blood sample obtain infant HIV1 DNA PCR , CBC differential , ALT Infants multiple birth eligible both/all infant eligible study assign study group Able breastfeed ( e.g. , mother infant alive condition apparent would prevent breastfeed ) Exclusion Criteria Infants : HIV DNA PCR positive birth ALT Grade 2 high birth Hemoglobin , absolute neutrophil count , platelet count Grade 3 high birth Skin rash Grade 2B ( urticaria ) , Grade 3 , Confirmed suspect clinical hepatitis Serious illness condition would interfere compliance study procedure</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>HIV Seronegativity</keyword>
	<keyword>Treatment Experienced</keyword>
	<keyword>Treatment Naive</keyword>
</DOC>